What are the key financial aspects an investor should look for in this 10-K?

Investors should focus on Item 6 (Selected Financial Data) for key historical financial metrics, and Item 8 (Financial Statements and Supplementary Data) for the audited balance sheets, income statements, and cash flow statements. Item 7 (Management's Discussion and Analysis) will provide management's perspective on the financial condition and results of operations.

Does the filing address potential risks for investors?

Yes, Item 1A (Risk Factors) is specifically dedicated to outlining the risks and uncertainties that could materially affect the company's business, financial condition, or results of operations. This is a crucial section for understanding potential downsides.

When and where can investors find information about the company's corporate governance and executive compensation?

Information regarding Directors, Executive Officers, Corporate Governance, and Executive Compensation can be found in Part III of the 10-K, specifically Items 10, 11, and 12. Additionally, the filing notes that specific details from the company's definitive proxy statement, to be filed in connection with the May 6, 2009 Annual Meeting, are incorporated by reference.

IDXX 10-K FY2008 Annual Report — Revenue, Net Income, EPS

Q: What is the primary business of IDEXX Laboratories Inc. as described in this filing?

Based on the table of contents, IDEXX Laboratories Inc. is primarily engaged in the animal health industry, offering diagnostic and information technology solutions for veterinarians. The 'Business' section (Item 1) likely details their specific product and service offerings in this market.

Summary

IDEXX Laboratories Inc. filed its 2008 10-K report on February 19, 2009, providing a comprehensive overview of its business operations and financial performance for the fiscal year ending December 30, 2008. The report details the company's activities within the animal health industry, focusing on its diagnostic and information technology solutions for veterinarians. Investors can gain insights into IDEXX's market position, competitive landscape, and strategic direction through this filing. Key sections of the report, such as "Business," "Risk Factors," and "Management's Discussion and Analysis of Financial Condition and Results of Operations," offer critical information regarding the company's revenue streams, profitability, and challenges. The filing also includes detailed financial statements, providing a transparent look at the company's assets, liabilities, and equity. While the provided excerpt is a table of contents, it indicates that the full report delves into crucial aspects like market risks, corporate governance, and executive compensation, which are vital for a thorough investor assessment.

Financial Highlights

31 data points

Beta

Revenue

$1.02B

0.5% Gross Margin

Net Income

$116.17M

0.1% Net Margin

EPS (Diluted)

$0.94

Cash & Equivalents

$78.87M

Free Cash Flow

$53.34M

Financial Statements

Beta

Revenue	$1.02B
Cost of Revenue	$494.26M
Gross Profit	$529.77M
R&D Expenses	$70.67M
Operating Income	$172.46M
Interest Expense	$4.59M
Net Income	$116.17M
EPS (Basic)	$0.97
EPS (Diluted)	$0.94
Shares Outstanding (Basic)	119.91M
Shares Outstanding (Diluted)	124.50M

Key Highlights

1The 10-K filing covers the fiscal year ending December 30, 2008, and was filed on February 19, 2009.
2IDEXX Laboratories operates within the animal health industry, providing diagnostic and information technology solutions.
3The report includes a detailed "Business" section outlining the company's products and services for veterinarians.
4"Risk Factors" are addressed, offering investors insights into potential challenges and uncertainties facing the company.
5"Management's Discussion and Analysis" provides commentary on financial condition and operational results.
6The filing incorporates by reference portions of the company's definitive proxy statement for the 2009 Annual Meeting.
7Financial statements and related supplementary data are presented in "Item 8" for a comprehensive financial review.

IDEXX LABORATORIES INC /DE Annual Report, Year Ended Dec 31, 2008

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions